Fei Xu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Fei Xu has a total of 279 co-authors. Here are the top co-authors by number of shared publications:
- Shusen Wang
Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China
19 shared publications Qianyi Lu
State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China
16 shared publicationsRuoxi Hong
Department of Medical Oncology, Sun Yat-sen University Cancer Centre, State Key Laboratory of Oncology in South China, Collaborative Innovation Centre for Cancer Medicine, Guangzhou, China
13 shared publicationsKuikui Jiang
Department of Medical Oncology, Sun Yat-sen University Cancer Centre, State Key Laboratory of Oncology in South China, Collaborative Innovation Centre for Cancer Medicine, Guangzhou, China
11 shared publicationsWen Xia
Department of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China
11 shared publicationsJiajia Huang
Department of Medical Oncology, Sun Yat-sen University Cancer Centre, State Key Laboratory of Oncology in South China, Collaborative Innovation Centre for Cancer Medicine, Guangzhou, China
9 shared publications
Latest Publications
- Open Access
- 11 November 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
Palbociclib, Fulvestrant, Trastuzumab, and Pyrotinib for Patients with Advanced Breast Cancer with Brain Metastases: A Prospective Multicenter Phase 2 Trial
Background : Patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-positive (HER2+) advanced breast cancer (ABC) face a high risk of brain metastases (BMs), yet prospective systemic‑treatment evidence for this subgroup is limited. We conducted a multicenter, single-arm, phase 2 trial evaluating a chemotherapy-sparing regimen of palbociclib, fulvestrant, trastuzumab, and pyrotinib in patients with HR+/HER2+ ABC and measurable BMs. The interim analysis suggested preliminary intracranial activity with manageable toxicity.Methods: Eligible patients had HR+/HER2+ ABC with measurable BMs and no prior local treatment to the target lesion. The regimen was administered until progression, unacceptable toxicity, or death. The primary endpoint was confirmed central nervous system objective response rate (CNS-ORR). Secondary endpoints included overall ORR, progression-free survival (PFS), CNS-PFS, overall survival (OS), and safety. We present the final analysis for 32 enrolled patients. Results: From Dec 2020 to Feb 2026, 32 patients were enrolled. For 29 response‑evaluable patients, confirmed CNS‑ORR was 58.6% (95%CI 40.7‑74.5) and overall ORR 62.1% (95%CI 44.0‑77.3). With median follow‑up of 32.5 months, median CNS-PFS was 9.6 months (95% CI: 5.3–13.9), and median overall PFS was 12.3 months (95% CI: 6.8–17.7). OS remained immature (5 deaths; 24‑month‑OS rate 80.7%). Post‑hoc analyses suggested numerically better PFS/CNS‑PFS in chemotherapy‑naïve patients, whereas prior trastuzumab did not impair efficacy. Frequent grade ≥3 adverse events comprised diarrhea (37.5%), neutropenia (28.1%) and leukopenia (15.6%), with no treatment‑related deaths. Conclusions: The chemotherapy-sparing quadruple regimen showed promising intracranial activity, systemic disease control, and manageable toxicity in HR+/HER2+ ABC patients with BMs.
- 11 November 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
Open AccessPalbociclib, Fulvestrant, Trastuzumab, and Pyrotinib for Patients with Advanced Breast Cancer with Brain Metastases: A Prospective Multicenter Phase 2 Trial
Background : Patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-positive (HER2+) advanced breast cancer (ABC) face a high risk of brain metastases (BMs), yet prospective systemic‑treatment evidence for this subgroup is limited. We conducted a multicenter, single-arm, phase 2 trial evaluating a chemotherapy-sparing regimen of palbociclib, fulvestrant, trastuzumab, and pyrotinib in patients with HR+/HER2+ ABC and measurable BMs. The interim analysis suggested preliminary intracranial activity with manageable toxicity.Methods: Eligible patients had HR+/HER2+ ABC with measurable BMs and no prior local treatment to the target lesion. The regimen was administered until progression, unacceptable toxicity, or death. The primary endpoint was confirmed central nervous system objective response rate (CNS-ORR). Secondary endpoints included overall ORR, progression-free survival (PFS), CNS-PFS, overall survival (OS), and safety. We present the final analysis for 32 enrolled patients. Results: From Dec 2020 to Feb 2026, 32 patients were enrolled. For 29 response‑evaluable patients, confirmed CNS‑ORR was 58.6% (95%CI 40.7‑74.5) and overall ORR 62.1% (95%CI 44.0‑77.3). With median follow‑up of 32.5 months, median CNS-PFS was 9.6 months (95% CI: 5.3–13.9), and median overall PFS was 12.3 months (95% CI: 6.8–17.7). OS remained immature (5 deaths; 24‑month‑OS rate 80.7%). Post‑hoc analyses suggested numerically better PFS/CNS‑PFS in chemotherapy‑naïve patients, whereas prior trastuzumab did not impair efficacy. Frequent grade ≥3 adverse events comprised diarrhea (37.5%), neutropenia (28.1%) and leukopenia (15.6%), with no treatment‑related deaths. Conclusions: The chemotherapy-sparing quadruple regimen showed promising intracranial activity, systemic disease control, and manageable toxicity in HR+/HER2+ ABC patients with BMs.
- Open Access
- 2 November 2026
- Published by Springer Nature in Signal Transduction and Targeted Therapy
- Vol. 11 (1) , 479
Neoadjuvant concurrent or sequential anthracycline-containing chemotherapy and HER2-targeted agents for HER2-positive breast cancer: a randomized phase 2 study (METIS)
The integration of anthracyclines with HER2-targeted agents in neoadjuvant therapy for HER2-positive breast cancer has been limited by cardiotoxicity concerns. This randomized phase II METIS trial (NCT04172259) assessed whether concurrent pegylated liposomal doxorubicin (PLD)-containing chemotherapy plus dual HER2 blockade (trastuzumab/pertuzumab) could improve efficacy without increasing cardiac risk. A total of 156 patients with stage II–III HER2-positive breast cancer were randomized to a PLD-based concurrent regimen or an epirubicin and cyclophosphamide (EC)-based sequential regimen. The PLD-based concurrent group achieved a higher pathological complete response (pCR) rate (67.5% vs. 48.7%; difference, 18.8%; 95% confidence interval [CI], 3.6–34.0; P = 0.033) compared with the EC-based sequential group, with greater benefit in hormone receptor–positive disease (58.7% vs. 36.7%) and stage II tumors (82.1% vs. 48.0%). After a median follow-up of 37.5 months, fewer event-free survival (EFS) events occurred in the PLD-based concurrent group (3 vs. 8), yielding a hazard ratio (HR) of 0.35 (95% CI, 0.09–1.32; P = 0.105). The estimated 3-year EFS rates were 96.0% (95% CI, 88.1–98.7) versus 90.7% (95% CI, 81.5–95.6). Achieving pCR was significantly associated with improved EFS (HR = 0.15; 95% CI, 0.03–0.71; P = 0.006). Cardiac safety was comparable, with no symptomatic cardiac dysfunction and only one grade ≥3 cardiotoxicity in the EC-based sequential group. These findings support PLD-based concurrent therapy with trastuzumab and pertuzumab as an effective and safe neoadjuvant option for high-risk HER2-positive breast cancer, warranting further evaluation in phase III trials.
- 2 November 2026
- Published by Springer Nature in Signal Transduction and Targeted Therapy
- Vol. 11 (1) , 479
Open AccessNeoadjuvant concurrent or sequential anthracycline-containing chemotherapy and HER2-targeted agents for HER2-positive breast cancer: a randomized phase 2 study (METIS)
The integration of anthracyclines with HER2-targeted agents in neoadjuvant therapy for HER2-positive breast cancer has been limited by cardiotoxicity concerns. This randomized phase II METIS trial (NCT04172259) assessed whether concurrent pegylated liposomal doxorubicin (PLD)-containing chemotherapy plus dual HER2 blockade (trastuzumab/pertuzumab) could improve efficacy without increasing cardiac risk. A total of 156 patients with stage II–III HER2-positive breast cancer were randomized to a PLD-based concurrent regimen or an epirubicin and cyclophosphamide (EC)-based sequential regimen. The PLD-based concurrent group achieved a higher pathological complete response (pCR) rate (67.5% vs. 48.7%; difference, 18.8%; 95% confidence interval [CI], 3.6–34.0; P = 0.033) compared with the EC-based sequential group, with greater benefit in hormone receptor–positive disease (58.7% vs. 36.7%) and stage II tumors (82.1% vs. 48.0%). After a median follow-up of 37.5 months, fewer event-free survival (EFS) events occurred in the PLD-based concurrent group (3 vs. 8), yielding a hazard ratio (HR) of 0.35 (95% CI, 0.09–1.32; P = 0.105). The estimated 3-year EFS rates were 96.0% (95% CI, 88.1–98.7) versus 90.7% (95% CI, 81.5–95.6). Achieving pCR was significantly associated with improved EFS (HR = 0.15; 95% CI, 0.03–0.71; P = 0.006). Cardiac safety was comparable, with no symptomatic cardiac dysfunction and only one grade ≥3 cardiotoxicity in the EC-based sequential group. These findings support PLD-based concurrent therapy with trastuzumab and pertuzumab as an effective and safe neoadjuvant option for high-risk HER2-positive breast cancer, warranting further evaluation in phase III trials.
- Open Access
- 13 May 2026
- Published by SAGE Publications in Therapeutic Advances in Medical Oncology
- Vol. 18
Dynamic inflammatory biomarkers as prognostic indicators in advanced breast cancer patients receiving PD-1 inhibitors
Background: While programmed cell death protein 1 (PD-1) inhibitors benefit breast cancer patients, simple predictors of their efficacy are lacking. Objectives: This study aimed to evaluate inflammatory markers as prognostic indicators for advanced breast cancer (ABC) patients receiving immunotherapy. Design: This is a single-center retrospective study of ABC patients treated with PD-1 inhibitors between January 2016 and June 2022. Methods: Clinicopathological parameters, tumor-infiltrating lymphocytes (TILs) levels, and inflammatory markers—C-reactive protein (CRP), neutrophil-to-lymphocyte ratio (NLR), and lymphocyte-to-monocyte ratio (LMR)—were collected from 116 ABC patients at baseline and after three cycles of immunotherapy (CRP3, NLR3, LMR3). Optimal cut-offs were defined using R software and associations with progression-free survival (PFS), overall survival (OS), and objective response rate were assessed. Results: Low baseline CRP, low NLR, and high LMR were significantly associated with improved PFS and OS (all p < 0.05) by Kaplan–Meier analysis. On multivariate analysis, low NLR3 and a reduced CRP3/CRP ratio independently predicted prolonged PFS ( p < 0.05). Patients with low CRP, reduced CRP3/CRP ratio, low NLR, and low NLR3 achieved better OS ( p < 0.05). Combining inflammatory markers with TIL status improved prognostic classification: TIL-deficient patients with high NLR3 (median PFS (mPFS): 2.89 months) or high CRP3/CRP ratio (mPFS: 1.90 months) had the poorest survival ( p < 0.05). Conclusion: CRP and NLR are promising biomarkers for predicting outcomes of PD-1 inhibitor therapy in ABC, with potential utility in individualizing immunotherapy strategies.
- 13 May 2026
- Published by SAGE Publications in Therapeutic Advances in Medical Oncology
- Vol. 18
Open AccessDynamic inflammatory biomarkers as prognostic indicators in advanced breast cancer patients receiving PD-1 inhibitors
Background: While programmed cell death protein 1 (PD-1) inhibitors benefit breast cancer patients, simple predictors of their efficacy are lacking. Objectives: This study aimed to evaluate inflammatory markers as prognostic indicators for advanced breast cancer (ABC) patients receiving immunotherapy. Design: This is a single-center retrospective study of ABC patients treated with PD-1 inhibitors between January 2016 and June 2022. Methods: Clinicopathological parameters, tumor-infiltrating lymphocytes (TILs) levels, and inflammatory markers—C-reactive protein (CRP), neutrophil-to-lymphocyte ratio (NLR), and lymphocyte-to-monocyte ratio (LMR)—were collected from 116 ABC patients at baseline and after three cycles of immunotherapy (CRP3, NLR3, LMR3). Optimal cut-offs were defined using R software and associations with progression-free survival (PFS), overall survival (OS), and objective response rate were assessed. Results: Low baseline CRP, low NLR, and high LMR were significantly associated with improved PFS and OS (all p < 0.05) by Kaplan–Meier analysis. On multivariate analysis, low NLR3 and a reduced CRP3/CRP ratio independently predicted prolonged PFS ( p < 0.05). Patients with low CRP, reduced CRP3/CRP ratio, low NLR, and low NLR3 achieved better OS ( p < 0.05). Combining inflammatory markers with TIL status improved prognostic classification: TIL-deficient patients with high NLR3 (median PFS (mPFS): 2.89 months) or high CRP3/CRP ratio (mPFS: 1.90 months) had the poorest survival ( p < 0.05). Conclusion: CRP and NLR are promising biomarkers for predicting outcomes of PD-1 inhibitor therapy in ABC, with potential utility in individualizing immunotherapy strategies.
- Open Access
- 15 April 2026
- Published by Springer Nature in Signal Transduction and Targeted Therapy
- Vol. 11 (1)
HDAC inhibitor tucidinostat and metronomic capecitabine plus endocrine therapy for patients with HR-positive HER2-negative advanced breast cancer after CDK4/6 inhibitors treatment: clinical findings and exploratory circulating tumor cell and ctDNA biomarker analyses of a multicenter, phase 2 study (SYSUCC-020 trial)
Treatment options for patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer (ABC) that progresses after CDK4/6 inhibitor (CDK4/6i) continue to evolve, and no single regimen has been established as the preferred standard of care. We conducted a phase 2 trial (SYSUCC-020, NCT05411380) to investigate the efficacy and safety of a novel combination of tucidinostat and metronomic capecitabine (mCAP) with endocrine therapy (ET) in patients following progression on CDK4/6i. This trial adopted a Simon two-stage design: eligible patients received tucidinostat plus metronomic capecitabine together with either an aromatase inhibitor (Cohort 1) or fulvestrant (Cohort 2), selected according to prior ET. Seventy-two female patients were screened and sixty-six patients were included in the efficacy and safety analyses. The median follow-up was 13.88 months (Interquartile range, 8.67-20.67) and the objective response rate was 25.8%, with 17 partial responses. The median progression-free survival (PFS) was 5.39 months (95% CI, 4.07-7.69), namely 6.93 months (95% CI, 4.76-12.22) in Cohort 1 and 3.98 months (95% CI, 2.79-7.59) in Cohort 2. Most patients (93.9%) experienced at least one adverse event. In addition, exploratory analyses of biomarkers indicated that the baseline TP53 mutation status (Wild type vs. mutated, 7.64 months vs. 3.55 months) and circulating tumor cell (CTC) status (CTC-negative vs. CTC-positive, 7.59 months vs. 3.78 months) were associated with the median PFS. Our study demonstrated that tucidinostat combined with mCAP and ET is efficacious and well-tolerated in patients with HR-positive HER2-negative ABC previously treated with CDK4/6i.
- 15 April 2026
- Published by Springer Nature in Signal Transduction and Targeted Therapy
- Vol. 11 (1)
Open AccessHDAC inhibitor tucidinostat and metronomic capecitabine plus endocrine therapy for patients with HR-positive HER2-negative advanced breast cancer after CDK4/6 inhibitors treatment: clinical findings and exploratory circulating tumor cell and ctDNA biomarker analyses of a multicenter, phase 2 study (SYSUCC-020 trial)
Treatment options for patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer (ABC) that progresses after CDK4/6 inhibitor (CDK4/6i) continue to evolve, and no single regimen has been established as the preferred standard of care. We conducted a phase 2 trial (SYSUCC-020, NCT05411380) to investigate the efficacy and safety of a novel combination of tucidinostat and metronomic capecitabine (mCAP) with endocrine therapy (ET) in patients following progression on CDK4/6i. This trial adopted a Simon two-stage design: eligible patients received tucidinostat plus metronomic capecitabine together with either an aromatase inhibitor (Cohort 1) or fulvestrant (Cohort 2), selected according to prior ET. Seventy-two female patients were screened and sixty-six patients were included in the efficacy and safety analyses. The median follow-up was 13.88 months (Interquartile range, 8.67-20.67) and the objective response rate was 25.8%, with 17 partial responses. The median progression-free survival (PFS) was 5.39 months (95% CI, 4.07-7.69), namely 6.93 months (95% CI, 4.76-12.22) in Cohort 1 and 3.98 months (95% CI, 2.79-7.59) in Cohort 2. Most patients (93.9%) experienced at least one adverse event. In addition, exploratory analyses of biomarkers indicated that the baseline TP53 mutation status (Wild type vs. mutated, 7.64 months vs. 3.55 months) and circulating tumor cell (CTC) status (CTC-negative vs. CTC-positive, 7.59 months vs. 3.78 months) were associated with the median PFS. Our study demonstrated that tucidinostat combined with mCAP and ET is efficacious and well-tolerated in patients with HR-positive HER2-negative ABC previously treated with CDK4/6i.
- Open Access
- 2 March 2026
- Published by Springer Nature in Communications Medicine
- Vol. 6 (1)
Efficacy and safety of eribulin plus gemcitabine as second-line treatment for recurrent HER2-negative breast cancer: a phase II, single-arm, open-label trial
Background Eribulin plus gemcitabine improves progression-free survival in chemotherapy-naive metastatic breast cancer patients, but its efficacy in second-line or later treatment remains unclear. Methods This single-arm, phase II study was conducted at 13 Chinese medical centers. Eligible patients had histologically confirmed human epidermal growth factor receptor 2 negative metastatic breast cancer and had received at least one prior taxane-containing chemotherapy regimen and anthracycline-containing regimens in the adjuvant setting. Patients received intravenous infusions of eribulin (1.4 mg/m2) and gemcitabine (1.0 g/m2) on days 1 and 8 of a 21-day cycle. Progression-free survival, objective response rate and disease control rate were assessed. Adverse events were also recorded. Results Here we show 70 patients took part in this study (71.4% hormone receptor positive/HER2 negative). Patients had received a median of three prior lines of systemic treatment. Overall, 48.6% have significant tumor shrinkage, 92.9% have tumor control, and median time without disease progression is 7.2 months (95% confidence interval, 5.5-10.9). Median time without disease progression is 8.4 months (hormone receptor positive) vs. 6.3 months (triple-negative, p = 0.1849). Grade 3–4 side effects mostly affect blood cells and are manageable. Conclusions Eribulin plus gemcitabine is effective and well-tolerated in patients with HER2-negative metastatic breast cancer needing second-line or later treatment, providing a valuable treatment option.
- 2 March 2026
- Published by Springer Nature in Communications Medicine
- Vol. 6 (1)
Open AccessEfficacy and safety of eribulin plus gemcitabine as second-line treatment for recurrent HER2-negative breast cancer: a phase II, single-arm, open-label trial
Background Eribulin plus gemcitabine improves progression-free survival in chemotherapy-naive metastatic breast cancer patients, but its efficacy in second-line or later treatment remains unclear. Methods This single-arm, phase II study was conducted at 13 Chinese medical centers. Eligible patients had histologically confirmed human epidermal growth factor receptor 2 negative metastatic breast cancer and had received at least one prior taxane-containing chemotherapy regimen and anthracycline-containing regimens in the adjuvant setting. Patients received intravenous infusions of eribulin (1.4 mg/m2) and gemcitabine (1.0 g/m2) on days 1 and 8 of a 21-day cycle. Progression-free survival, objective response rate and disease control rate were assessed. Adverse events were also recorded. Results Here we show 70 patients took part in this study (71.4% hormone receptor positive/HER2 negative). Patients had received a median of three prior lines of systemic treatment. Overall, 48.6% have significant tumor shrinkage, 92.9% have tumor control, and median time without disease progression is 7.2 months (95% confidence interval, 5.5-10.9). Median time without disease progression is 8.4 months (hormone receptor positive) vs. 6.3 months (triple-negative, p = 0.1849). Grade 3–4 side effects mostly affect blood cells and are manageable. Conclusions Eribulin plus gemcitabine is effective and well-tolerated in patients with HER2-negative metastatic breast cancer needing second-line or later treatment, providing a valuable treatment option.
- Open Access
- 1 December 2025
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 30 (12)
Estradiol levels in women with hormone receptor-positive advanced breast cancer on fulvestrant therapy
Background: Limited data are available on estradiol (E2) levels during fulvestrant treatment in women with hormone receptor-positive breast cancer. Methods: We measured plasma E2 levels in women receiving fulvestrant using liquid chromatography–tandem mass spectrometry. Patient characteristics and treatment efficacy were assessed in relation to E2 levels. A cutoff of 2.72 pg/mL was used because it defines E2 suppression and postmenopausal status. Results: A total of 69 women were enrolled, with a median age of 48 years. The median duration of fulvestrant treatment was 11.6 months. The median E2 level across the cohort was 3.60 pg/mL, with considerable interindividual variability (range: 1.11-526.13 pg/mL), and 49 women (71.0%) had E2 levels above 2.72 pg/mL. Eleven women (15.9%) had premenopausal E2 levels (>10 pg/mL). During a median follow-up period of 8.4 months, there was no statistically significant difference in progression-free survival (PFS) between women with E2 levels >2.72 pg/mL and those with E2 levels ≤2.72 pg/mL (P = .391). However, among women who benefited from first- or second-line fulvestrant therapy (PFS > 6 months), those with E2 levels >2.72 pg/mL exhibited significantly poorer PFS compared to those with E2 levels ≤2.72 pg/mL (P = .043). Conclusions: These findings support the need for E2 monitoring in women receiving fulvestrant therapy to better assess E2 status and its association with treatment efficacy.
- 1 December 2025
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 30 (12)
Open AccessEstradiol levels in women with hormone receptor-positive advanced breast cancer on fulvestrant therapy
Background: Limited data are available on estradiol (E2) levels during fulvestrant treatment in women with hormone receptor-positive breast cancer. Methods: We measured plasma E2 levels in women receiving fulvestrant using liquid chromatography–tandem mass spectrometry. Patient characteristics and treatment efficacy were assessed in relation to E2 levels. A cutoff of 2.72 pg/mL was used because it defines E2 suppression and postmenopausal status. Results: A total of 69 women were enrolled, with a median age of 48 years. The median duration of fulvestrant treatment was 11.6 months. The median E2 level across the cohort was 3.60 pg/mL, with considerable interindividual variability (range: 1.11-526.13 pg/mL), and 49 women (71.0%) had E2 levels above 2.72 pg/mL. Eleven women (15.9%) had premenopausal E2 levels (>10 pg/mL). During a median follow-up period of 8.4 months, there was no statistically significant difference in progression-free survival (PFS) between women with E2 levels >2.72 pg/mL and those with E2 levels ≤2.72 pg/mL (P = .391). However, among women who benefited from first- or second-line fulvestrant therapy (PFS > 6 months), those with E2 levels >2.72 pg/mL exhibited significantly poorer PFS compared to those with E2 levels ≤2.72 pg/mL (P = .043). Conclusions: These findings support the need for E2 monitoring in women receiving fulvestrant therapy to better assess E2 status and its association with treatment efficacy.
- Open Access
- 10 April 2025
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 43 (11) , 1314-1324
Metronomic Capecitabine Plus Aromatase Inhibitor as Initial Therapy in Patients With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer: The Phase III MECCA Trial
PURPOSE: The effects of metronomic chemotherapy plus endocrine therapy have yet to be elucidated through a randomized phase III clinical trial. METHODS: Randomized clinical trials were conducted at 12 centers in China from August 22, 2017, to September 24, 2021, and the final follow-up date was August 25, 2023. Patients with hormone receptor–positive, human epidermal growth factor receptor 2 (HER2)–negative metastatic breast cancer (MBC) who had no previous systemic therapy in the metastatic setting were enrolled. Participants were 1:1 assigned to receive either metronomic capecitabine plus an aromatase inhibitor (AI) or AI alone. The primary end point was progression-free survival (PFS). Secondary end points included overall survival (OS), objective response rate, disease control rate (defined as disease controlled for ≥24 weeks), and safety. RESULTS: A total of 263 patients were randomly assigned, among which 254 patients formed the full analysis set. At the median follow-up time of 50.7 months, 203 PFS events occurred. The metronomic capecitabine plus AI arm exhibited a median PFS of 20.9 months compared with 11.9 months in the AI arm (hazard ratio [HR], 0.58 [95% CI, 0.43 to 0.76]). The median OS was not reached in the combination arm and was 45.1 months in the AI arm (HR, 0.58 [95% CI, 0.37 to 0.93]). The most common adverse events were palmar-plantar erythrodysesthesia and peripheral neuropathy; grade 3 events occurred in 15.1% of the patients receiving combination treatment. CONCLUSION: The MECCA trial demonstrated a significant improvement in PFS and OS with first-line metronomic capecitabine plus AI compared with AI alone in patients with hormone receptor-positive+/HER2-negative MBC. Both treatment arms exhibited tolerable safety profiles consistent with previous reports.
- 10 April 2025
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 43 (11) , 1314-1324
Open AccessMetronomic Capecitabine Plus Aromatase Inhibitor as Initial Therapy in Patients With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer: The Phase III MECCA Trial
PURPOSE: The effects of metronomic chemotherapy plus endocrine therapy have yet to be elucidated through a randomized phase III clinical trial. METHODS: Randomized clinical trials were conducted at 12 centers in China from August 22, 2017, to September 24, 2021, and the final follow-up date was August 25, 2023. Patients with hormone receptor–positive, human epidermal growth factor receptor 2 (HER2)–negative metastatic breast cancer (MBC) who had no previous systemic therapy in the metastatic setting were enrolled. Participants were 1:1 assigned to receive either metronomic capecitabine plus an aromatase inhibitor (AI) or AI alone. The primary end point was progression-free survival (PFS). Secondary end points included overall survival (OS), objective response rate, disease control rate (defined as disease controlled for ≥24 weeks), and safety. RESULTS: A total of 263 patients were randomly assigned, among which 254 patients formed the full analysis set. At the median follow-up time of 50.7 months, 203 PFS events occurred. The metronomic capecitabine plus AI arm exhibited a median PFS of 20.9 months compared with 11.9 months in the AI arm (hazard ratio [HR], 0.58 [95% CI, 0.43 to 0.76]). The median OS was not reached in the combination arm and was 45.1 months in the AI arm (HR, 0.58 [95% CI, 0.37 to 0.93]). The most common adverse events were palmar-plantar erythrodysesthesia and peripheral neuropathy; grade 3 events occurred in 15.1% of the patients receiving combination treatment. CONCLUSION: The MECCA trial demonstrated a significant improvement in PFS and OS with first-line metronomic capecitabine plus AI compared with AI alone in patients with hormone receptor-positive+/HER2-negative MBC. Both treatment arms exhibited tolerable safety profiles consistent with previous reports.
- Open Access
- 8 April 2025
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 13 (4) , e011314
Bevacizumab, tislelizumab and nab-paclitaxel for previously untreated metastatic triple-negative breast cancer: a phase II trial
Background: Optimal first-line therapy for metastatic triple-negative breast cancer (mTNBC) varied in different situations. This phase II trial explores the efficacy and safety of combination regimens with be vacizumab, ti slelizumab and na b-paclitaxel (BETINA) in first-line setting for mTNBC. Methods: Patients with previously untreated advanced TNBC received tislelizumab 200 mg and bevacizumab on day 1 and nab-paclitaxel 125 mg/m 2 on day 1, day 8 in 3-week cycles. Patients were randomized to bevacizumab 7.5 mg/kg or 15 mg/kg. The primary endpoint was investigator-assessed objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors V.1.1. Secondary endpoints included progression-free survival (PFS), overall survival (OS), and safety. The trial was registered at the Chinese Clinical Trial Registry (No. ChiCTR2200058567). Results: 30 female patients were enrolled from March 11, 2021 to February 5, 2024. Nine patients receiving bevacizumab 15 mg/kg experienced significantly higher hypertension rates versus 7.5 mg/kg (55.5% vs 0%), prompting subsequent enrollment of 12 additional patients at 7.5 mg/kg. By November 30, 2024, the ORR was 73.3% and the disease control rate was 90.0%, while the median PFS was 6.0 months and the median OS was 19.8 months. No new safety signal was reported. Common treatment-related adverse events (AEs) included peripheral sensory neuropathy (83.3%), dyspepsia (70.0%), anemia (70.0%), leukocytopenia (66.7%), and pruritus (53.3%). Hypothyroidism (30.0%) was the most frequent immune-related AE. Biomarker analysis indicated that lower baseline interleukin (IL)-1α was associated with poor survival, while IL-2, vascular endothelial growth factor-A and insulin-like growth factor binding protein-7 levels significantly decreased at progression. RNA sequencing highlighted the enrichment of the fatty acid metabolism pathway in poor responders. Conclusions: BETINA study demonstrated promising efficacy and favorable tolerance in treating patients with mTNBC with bevacizumab with tislelizumab and nab-paclitaxel.
- 8 April 2025
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 13 (4) , e011314
Open AccessBevacizumab, tislelizumab and nab-paclitaxel for previously untreated metastatic triple-negative breast cancer: a phase II trial
Background: Optimal first-line therapy for metastatic triple-negative breast cancer (mTNBC) varied in different situations. This phase II trial explores the efficacy and safety of combination regimens with be vacizumab, ti slelizumab and na b-paclitaxel (BETINA) in first-line setting for mTNBC. Methods: Patients with previously untreated advanced TNBC received tislelizumab 200 mg and bevacizumab on day 1 and nab-paclitaxel 125 mg/m 2 on day 1, day 8 in 3-week cycles. Patients were randomized to bevacizumab 7.5 mg/kg or 15 mg/kg. The primary endpoint was investigator-assessed objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors V.1.1. Secondary endpoints included progression-free survival (PFS), overall survival (OS), and safety. The trial was registered at the Chinese Clinical Trial Registry (No. ChiCTR2200058567). Results: 30 female patients were enrolled from March 11, 2021 to February 5, 2024. Nine patients receiving bevacizumab 15 mg/kg experienced significantly higher hypertension rates versus 7.5 mg/kg (55.5% vs 0%), prompting subsequent enrollment of 12 additional patients at 7.5 mg/kg. By November 30, 2024, the ORR was 73.3% and the disease control rate was 90.0%, while the median PFS was 6.0 months and the median OS was 19.8 months. No new safety signal was reported. Common treatment-related adverse events (AEs) included peripheral sensory neuropathy (83.3%), dyspepsia (70.0%), anemia (70.0%), leukocytopenia (66.7%), and pruritus (53.3%). Hypothyroidism (30.0%) was the most frequent immune-related AE. Biomarker analysis indicated that lower baseline interleukin (IL)-1α was associated with poor survival, while IL-2, vascular endothelial growth factor-A and insulin-like growth factor binding protein-7 levels significantly decreased at progression. RNA sequencing highlighted the enrichment of the fatty acid metabolism pathway in poor responders. Conclusions: BETINA study demonstrated promising efficacy and favorable tolerance in treating patients with mTNBC with bevacizumab with tislelizumab and nab-paclitaxel.
- Open Access
- 13 June 2024
- Published by Springer Nature in npj Breast Cancer
- Vol. 10 (1) , 1-7
Pyrotinib and trastuzumab plus palbociclib and fulvestrant in HR+/HER2+ breast cancer patients with brain metastasis
Human epidermal growth factor receptor 2-positive (HER2+) breast cancer (BC) patients are at a high risk of developing metastases in the brain. However, research focusing on treatment strategies for hormonal receptor positive (HR+), HER2+ BC patients with brain metastases (BM) remains limited. Thus, a multi-center, prospective trial was conducted in China. Women over the age of 18 who were naive to whole brain radiotherapy and had estrogen receptor (ER)/progesterone-receptor (PgR) positive, HER2+ BM were treated with palbociclib, fulvestrant, trastuzumab and pyrotinib, until disease progression or the development of intolerable side effects. The primary endpoint was objective response rate (ORR) in the central nervous system (CNS). This ongoing study is still recruiting participants and is registered with ClinicalTrials.gov (NCT04334330). This report presents the findings from an interim analysis. From December 4, 2020, to November 2, 2022, 15 patients were enrolled. Among the 14 patients who were evaluable for clinical response, the ORR was 35.7% (95% CI: 12.8–64.9%), with a CNS–ORR of 28.6% (95% CI: 8.4–58.1%). The median follow-up period was 6.3 months (range, 2.1–14.3 months), during which the median progression-free survival (PFS) was 10.6 months (95% CI: 4.3–16.9 months), and the median time to CNS progression was 8.5 months (95% CI: 5.9–11.1 months). The most common adverse event was diarrhea (93%), with 33% having grade 3 and 6.7% having grade 4. The study suggests that the combination of palbociclib, trastuzumab, pyrotinib and fulvestrant offers a promising chemo-free treatment strategy for HR+, HER2+ BC patients with BM.
- 13 June 2024
- Published by Springer Nature in npj Breast Cancer
- Vol. 10 (1) , 1-7
Open AccessPyrotinib and trastuzumab plus palbociclib and fulvestrant in HR+/HER2+ breast cancer patients with brain metastasis
Human epidermal growth factor receptor 2-positive (HER2+) breast cancer (BC) patients are at a high risk of developing metastases in the brain. However, research focusing on treatment strategies for hormonal receptor positive (HR+), HER2+ BC patients with brain metastases (BM) remains limited. Thus, a multi-center, prospective trial was conducted in China. Women over the age of 18 who were naive to whole brain radiotherapy and had estrogen receptor (ER)/progesterone-receptor (PgR) positive, HER2+ BM were treated with palbociclib, fulvestrant, trastuzumab and pyrotinib, until disease progression or the development of intolerable side effects. The primary endpoint was objective response rate (ORR) in the central nervous system (CNS). This ongoing study is still recruiting participants and is registered with ClinicalTrials.gov (NCT04334330). This report presents the findings from an interim analysis. From December 4, 2020, to November 2, 2022, 15 patients were enrolled. Among the 14 patients who were evaluable for clinical response, the ORR was 35.7% (95% CI: 12.8–64.9%), with a CNS–ORR of 28.6% (95% CI: 8.4–58.1%). The median follow-up period was 6.3 months (range, 2.1–14.3 months), during which the median progression-free survival (PFS) was 10.6 months (95% CI: 4.3–16.9 months), and the median time to CNS progression was 8.5 months (95% CI: 5.9–11.1 months). The most common adverse event was diarrhea (93%), with 33% having grade 3 and 6.7% having grade 4. The study suggests that the combination of palbociclib, trastuzumab, pyrotinib and fulvestrant offers a promising chemo-free treatment strategy for HR+, HER2+ BC patients with BM.
- Open Access
- 15 April 2024
- Published by Korean Cancer Association in Cancer Research and Treatment
- Vol. 56 (2) , 513-521
Pyrotinib Combined with Vinorelbine in Patients with Previously Treated HER2-Positive Metastatic Breast Cancer: A Multicenter, Single-Arm, Prospective Study
Purpose This study aims to evaluate the efficacy and safety of a new combination treatment of vinorelbine and pyrotinib in human epidermal growth factor receptor 2 (HER2)–positive metastatic breast cancer (MBC) and provide higher level evidence for clinical practice.Materials and Methods This was a prospective, single-arm, phase 2 trial conducted at three institutions in China. Patients with HER2-positive MBC, who had previously been treated with trastuzumab plus a taxane or trastuzumab plus pertuzumab combined with a chemotherapeutic agent, were enrolled between March 2020 and December 2021. All patients received pyrotinib 400 mg orally once daily plus vinorelbine 25 mg/m2 intravenously or 60-80 mg/m2 orally on day 1 and day 8 of 21-day cycle. The primary endpoint was progression-free survival (PFS), and the secondary endpoints included the objective response rate (ORR), disease control rate (DCR), overall survival, and safety.Results A total of 39 patients were enrolled. All patients had been pretreated with trastuzumab and 23.1% (n=9) of them had accepted trastuzumab plus pertuzumab. The median follow-up time was 16.3 months (95% confidence interval [CI], 5.3 to 27.2), and the median PFS was 6.4 months (95% CI, 4.0 to 8.8). The ORR was 43.6% (95% CI, 27.8% to 60.4%) and the DCR was 84.6% (95% CI, 69.5% to 94.1%). The median PFS of patients with versus without prior pertuzumab treatment was 4.6 and 8.3 months (p=0.017). The most common grade 3/4 adverse events were diarrhea (28.2%), neutrophil count decreased (15.4%), white blood cell count decreased (7.7%), vomiting (5.1%), and anemia (2.6%).Conclusion Pyrotinib plus vinorelbine showed promising efficacy and tolerable toxicity as second-line treatment in patients with HER2-positive MBC.
- 15 April 2024
- Published by Korean Cancer Association in Cancer Research and Treatment
- Vol. 56 (2) , 513-521
Open AccessPyrotinib Combined with Vinorelbine in Patients with Previously Treated HER2-Positive Metastatic Breast Cancer: A Multicenter, Single-Arm, Prospective Study
Purpose This study aims to evaluate the efficacy and safety of a new combination treatment of vinorelbine and pyrotinib in human epidermal growth factor receptor 2 (HER2)–positive metastatic breast cancer (MBC) and provide higher level evidence for clinical practice.Materials and Methods This was a prospective, single-arm, phase 2 trial conducted at three institutions in China. Patients with HER2-positive MBC, who had previously been treated with trastuzumab plus a taxane or trastuzumab plus pertuzumab combined with a chemotherapeutic agent, were enrolled between March 2020 and December 2021. All patients received pyrotinib 400 mg orally once daily plus vinorelbine 25 mg/m2 intravenously or 60-80 mg/m2 orally on day 1 and day 8 of 21-day cycle. The primary endpoint was progression-free survival (PFS), and the secondary endpoints included the objective response rate (ORR), disease control rate (DCR), overall survival, and safety.Results A total of 39 patients were enrolled. All patients had been pretreated with trastuzumab and 23.1% (n=9) of them had accepted trastuzumab plus pertuzumab. The median follow-up time was 16.3 months (95% confidence interval [CI], 5.3 to 27.2), and the median PFS was 6.4 months (95% CI, 4.0 to 8.8). The ORR was 43.6% (95% CI, 27.8% to 60.4%) and the DCR was 84.6% (95% CI, 69.5% to 94.1%). The median PFS of patients with versus without prior pertuzumab treatment was 4.6 and 8.3 months (p=0.017). The most common grade 3/4 adverse events were diarrhea (28.2%), neutrophil count decreased (15.4%), white blood cell count decreased (7.7%), vomiting (5.1%), and anemia (2.6%).Conclusion Pyrotinib plus vinorelbine showed promising efficacy and tolerable toxicity as second-line treatment in patients with HER2-positive MBC.